Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study (RTB-006)

Angus W. Thomson PhD DSc

Status and phase: Active, not recruiting; Phase 1

Conditions: Renal Transplant Recipients; Kidney Transplant

Treatments: Biological: DCreg: 1.2 million cells/kg+SOC; Biological: DCreg: 0.5 million cells/kg+SOC; Biological: DCreg:2.5 to 5.0 million cells/kg+SOC

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT03726307

STUDY19040393

U01AI136779 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This study will evaluate the safety and feasibility of treatment involving a single infusion of donor-derived regulatory dendritic cells (DCreg) in first time, living donor renal transplant recipients.

DCreg will be prepared from monocytes obtained by leukapheresis from prospective (non-mobilized) living kidney donors and infused into the respective recipients 7 days before renal transplantation. This study will enroll 28 subjects (14 recipients, 14 donors). The duration of follow-up will be:

• 1 week following the leukapheresis procedure for donors and
• 2 years following their DCreg infusion for kidney recipients.

Full description

This clinical trial is a single-center, open-label, dose-escalation, phase 1 study, enrolling N=14 de novo kidney transplant recipients and their respective living donors. The study objective is to evaluate the safety and feasibility of a single infusion of donor-derived regulatory dendritic cell (DCreg) treatment.

Transplant recipients will receive combination immunosuppressive agents according to the site's Standard of Care (SOC) regimen, with two exceptions:

• mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and
• the pre-transplant dose of MPA will be half the standard post-transplant dose, due to increased drug bioavailability in recipients with low kidney function defined by glomerular filtration rate (GFR).

Consequently, participants will be maintained on triple immunosuppressive therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide.

Note: Participants will not be withdrawn from known effective therapy for the purpose of participating in this research.

Enrollment: 28 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Donor Eligibility Criteria:

• Able to understand and provide informed consent;
• Male or female >/= 18 years of age
• Meets all standard institutional criteria for kidney donation and Health Agency criteria for kidney donation;
• For females of childbearing potential, a negative urine or serum pregnancy test;
• Negative for Human Immunodeficiency Virus type 1 (HIV) -1 (antigen and Nucleic Acid Testing (NAT)), HIV-2, Human T-cell leukemia virus type 1 (HTLV-1), and HTLV-2;
• Negative for hepatitis C (antibody and NAT), hepatitis B (surface antigen and core antibody), and Treponema pallidum infection;
• Negative for West Nile Virus;
• Negative health history for Creutzfeldt-Jakob disease;
• No live vaccines within 8 weeks prior to leukapheresis;
• No medical condition(s) that the investigator deems incompatible with participation in the trial; and
• No use of investigational drugs within 12 weeks of participation.

Recipient Inclusion Criteria:

• Must be able to understand and provide informed consent;
• Is >/= 18 years old at the time of informed consent;
• Is undergoing a living donor renal transplant;
• For females of childbearing potential, a negative urine or serum pregnancy test upon study entry
• The candidate agrees to use contraception with a method that is more than 80% effective (see FDA Office of Women's Health (http://www.fda.gov/birthcontrol). Female participants of child-bearing potential must consult with their physician and determine the most suitable method(s) to be used from one month before study treatment begins until one month after study completion;
• Cytomegalovirus (CMV) seropositive or, if CMV seronegative must be receiving a kidney from a CMV seronegative donor;
• Has a negative purified protein derivative (PPD) or negative testing for tuberculosis using an approved IGRA blood test, such as QuantiFERON®-Gold TB or T-SPOT-TB assay OR has completed treatment for latent tuberculosis and has a negative chest x-ray. PPD or IGRA testing must occur within 52 weeks before transplant. These requirements apply as well to prior recipients of Bacille Calmette-Guérin (BCG) vaccination;
• Meets all standard institutional and Health Agency criteria for kidney transplant.
• Vaccines up to date as per DAIT guidance for patients in transplant trials (Refer to Manual of Operations).

Study Exclusion Criteria:

• Panel Reactive Antibody (PRA >20%);
• Positive T or B Cell Flow Crossmatch prior to transplant;
• Presence of donor specific antibody (DSA) ≥ to mean fluorescence intensity (MFI) of 1000, or DSA between 500 and 1000, if a specific shared epitope pattern is present;
• Recipient of multi-organ transplant;
• Any prior renal or extra-renal transplant with HLA class II antigen mismatch shared with prior organ;
• Epstein-Barr Virus (EBV) Immunoglobulin G (IgG) negative if the donor is EBV positive;
• Seropositivity for HIV-1, hepatitis B core antigen, or hepatitis C virus (HCV) antibody (if hepatitis C antibody positive, confirm negative infection by HCV RNA), or positivity for hepatitis B surface antigen;
• History of malignancy witin the past 5 years unless standard institutional criteria detailed in Appendix 6 have been met;
• High risk for recurrence of renal disease: Hemolytic Uremic Syndrome Thrombotic Thrombocytopenic Purpura (HUS-TTP); Focal Segmental Glomerular Sclerosis (FSGS); or Aggressive native kidney disease.
• Compensated and decompensated cirrhosis of liver and/or portal hypertension;
• Chronic Obstructive Pulmonary Disease requiring nasal oxygen, and/or pulmonary hypertension (mean pulmonary pressure >45mm/hg);
• Any history of stroke with neurological deficit;
• Any condition that, in the opinion of the investigator, confers excessive risk for participation in this phase 1 study;
• Presence of a condition that requires treatment with an immunosuppressive agent, other than a physiologic dose of corticosteroid;
• Live vaccines within 8 weeks prior to transplant;
• Use of investigational drugs within 12 weeks of participation;
• Woman receiving a kidney from a man who has fathered her child(ren), whether or not carried to term; or
• Woman receiving a kidney from her biological child.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

28 participants in 3 patient groups

DCreg: 0.5 million cells/kg+SOC

Experimental group

Description:

N=3 participants will receive 0.5 (± 0.1) million cells/kg body weight as a single infusion. Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions: * mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and * the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR). Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide.

Treatment:

Biological: DCreg: 0.5 million cells/kg+SOC

DCreg: 1.2 million cells/kg+SOC

Experimental group

Description:

N=3 participants will receive 1.2 (± 0.2) million cells/kg body weight as a single infusion. Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions: * mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and * the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR). Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide.

Treatment:

Biological: DCreg: 1.2 million cells/kg+SOC

DCreg:2.5 to 5.0 million cells/kg+SOC

Experimental group

Description:

N=8 participants will receive 25 to 5.0 million cells /kg body weight as a single infusion. Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions: * mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and * the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR). Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide.

Treatment:

Biological: DCreg:2.5 to 5.0 million cells/kg+SOC